It is reported that over the past 14 years,the"China Good Medical Engineer"selection has become the most influential,highly watched,and widely recognized authoritative award event in the industry.Being selected signifies receiving high acclaim and recognition from both internal and external professional judges,demonstrating the strong capabilities of outstanding innovative companies like KEENSEA Medical Technology in the medical innovation field.It is worth mentioning that KEENSEA Medical Technology's endoscopy project has recently been honored with the"Most Investment Value Award"at the 10th China Medical Industry Innovation Competition.
In recent years,KEENSEA Medical Technology has achieved numerous significant breakthroughs in the research and development of endoscopy technology,covering a range of products from 4K ultra-high-definition endoscopy systems to 3D and naked-eye 3D image processing systems,and further to 4K fluorescence and future multi-spectrum ultra-high-definition endoscopy systems.
According to SmartKarma,the development of domestic endoscopes in China has entered a high-speed growth phase,with the gap between domestic and foreign products gradually narrowing.Domestic substitution has become an irresistible trend.According to forecasts by Frost&Sullivan,the domestic penetration rate of endoscopes in China is expected to reach 18.3%by 2025 and is projected to increase to 35.2%by 2030.It is worth noting that KEENSEA Medical Technology's latest Endo Next series True 4K 3D 4MOS ultra-high-definition fluorescence endoscopy system was successfully launched in July 2023.This endoscopy system integrates the"4K+3D+fluorescence"triad technology,offering a more precise solution for minimally invasive surgery.
